These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 25995442)

  • 41. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.
    Dwivedi SK; Mustafi SB; Mangala LS; Jiang D; Pradeep S; Rodriguez-Aguayo C; Ling H; Ivan C; Mukherjee P; Calin GA; Lopez-Berestein G; Sood AK; Bhattacharya R
    Oncotarget; 2016 Mar; 7(12):15093-104. PubMed ID: 26918603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
    Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; ; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; deFazio A; Norris MD; MacGregor S; Haber M; Henderson MJ
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
    Fleury H; Carmona E; Morin VG; Meunier L; Masson JY; Tonin PN; Provencher D; Mes-Masson AM
    Oncotarget; 2017 Jun; 8(25):40152-40168. PubMed ID: 27374179
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
    Kanakkanthara A; Hou X; Ekstrom TL; Zanfagnin V; Huehls AM; Kelly RL; Ding H; Larson MC; Vasmatzis G; Oberg AL; Kaufmann SH; Mansfield AS; Weroha SJ; Karnitz LM
    Cancer Res; 2022 Jan; 82(2):307-319. PubMed ID: 34810199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Calpain system protein expression and activity in ovarian cancer.
    Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
    Yasukawa M; Fujihara H; Fujimori H; Kawaguchi K; Yamada H; Nakayama R; Yamamoto N; Kishi Y; Hamada Y; Masutani M
    Int J Mol Sci; 2016 Feb; 17(3):272. PubMed ID: 26927065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    Brandt S; Samartzis EP; Zimmermann AK; Fink D; Moch H; Noske A; Dedes KJ
    BMC Cancer; 2017 Jan; 17(1):44. PubMed ID: 28073364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.
    Choi YE; Battelli C; Watson J; Liu J; Curtis J; Morse AN; Matulonis UA; Chowdhury D; Konstantinopoulos PA
    Oncotarget; 2014 May; 5(9):2678-87. PubMed ID: 24798692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Herpes virus microRNA expression and significance in serous ovarian cancer.
    Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
    PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
    Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.
    Moudry P; Watanabe K; Wolanin KM; Bartkova J; Wassing IE; Watanabe S; Strauss R; Troelsgaard Pedersen R; Oestergaard VH; Lisby M; Andújar-Sánchez M; Maya-Mendoza A; Esashi F; Lukas J; Bartek J
    J Cell Biol; 2016 Feb; 212(3):281-8. PubMed ID: 26811421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
    Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
    Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
    Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
    Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
    Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
    Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.